奥瑞珠单抗治疗复发型多发性硬化的临床与MRI疗效起效时间
该研究评估奥瑞珠单抗在复发缓解型多发性硬化(RRMS)中抑制MRI病灶活动的起效时间,以及复发型多发性硬化(RMS)中降低复发率的起效时间。II期试验显示,奥瑞珠单抗第4周即减少新发T1钆增强病灶(vs 安慰剂),第8周减少新发或扩大T2病灶(vs 安慰剂和IFNβ-1a)。III期OPERA I/II汇总分析显示,奥瑞珠单抗在前8周内即显著降低年化复发率并延长至首次复发时间(vs 皮下IFNβ-1a)。
要点
- 奥瑞珠单抗第4周即显著减少RRMS患者新发T1钆增强病灶(vs 安慰剂)。
- 第8周时奥瑞珠单抗较IFNβ-1a显著减少新发或扩大T2病灶。
- RMS患者前8周内奥瑞珠单抗即显著降低年化复发率和首次复发风险。
核心结论
- 奥瑞珠单抗治疗RRMS和RMS后,急性MRI病灶活动和临床疾病活动均被快速抑制。
研究设计与样本
- II期试验在RRMS患者中按月进行脑MRI评估,比较安慰剂、奥瑞珠单抗600 mg和肌注IFNβ-1a 30 μg。
- III期OPERA I和OPERA II试验汇总分析RMS患者,比较奥瑞珠单抗600 mg和皮下IFNβ-1a 44 μg的复发率。
主要发现
- RRMS患者中,奥瑞珠单抗较安慰剂在第4周显著减少新发T1钆增强病灶数(p=0.042)。
- RRMS患者中,奥瑞珠单抗较肌注IFNβ-1a在第8周显著减少新发T1钆增强病灶数(p<0.001)。
- RRMS患者中,奥瑞珠单抗较安慰剂和IFNβ-1a均显著减少第4至8周新发或扩大T2病灶数(均p<0.001)。
- RMS患者中,奥瑞珠单抗较皮下IFNβ-1a在前8周内显著降低年化复发率(p=0.005)和至首次方案定义复发时间的概率(p=0.014)。
临床怎么用
- 对于RRMS和RMS患者,奥瑞珠单抗可在4周内抑制MRI活动、8周内抑制临床疾病活动,支持早期启动治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the onset of ocrelizumab efficacy on brain MRI measures of disease activity in the phase II study in relapsing-remitting multiple sclerosis (RRMS), and relapse rate in the pooled phase III studies in relapsing multiple sclerosis (RMS). METHODS: Brain MRI activity was determined in the phase II trial at monthly intervals in patients with RRMS receiving placebo, ocrelizumab (600 mg), or intramuscular interferon (IFN) β-1a (30 μg). Annualized relapse rate (ARR; over various epochs) and time to first relapse were analyzed in the pooled population of the phase III OPERA (A Study of Ocrelizumab in Comparison With Interferon Beta-1a [Rebif] in Participants With Relapsing Multiple Sclerosis) I and OPERA II trials in patients with RMS receiving ocrelizumab (600 mg) or subcutaneous IFN-β-1a (44 μg). RESULTS: In patients with RRMS, ocrelizumab reduced the number of new T1 gadolinium-enhancing lesions by week 4 vs placebo (p = 0.042) and by week 8 vs intramuscular IFN-β-1a (p < 0.001). Ocrelizumab also reduced the number of new or enlarging T2 lesions appearing between weeks 4 and 8 vs both placebo and IFN-β-1a (both p < 0.001). In patients with RMS, ocrelizumab significantly reduced ARR (p = 0.005) and the probability of time to first protocol-defined relapse (p = 0.014) vs subcutaneous IFN-β-1a within the first 8 weeks. CONCLUSION: Epoch analysis of MRI-measured lesion activity in the phase II study and relapse rate in the phase III studies consistently revealed a rapid suppression of acute MRI and clinical disease activity following treatment initiation with ocrelizumab in patients with RRMS and RMS, respectively. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with RRMS and RMS, ocrelizumab suppressed MRI activity within 4 weeks and clinical disease activity within 8 weeks.
引用
- Barkhof F, Kappos L, Wolinsky JS, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology. 2019. PMID: 31484710. doi:10.1212/WNL.0000000000008189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。